CNBC 快讯 5月18日 10:49 Regeneron 皮肤癌联合疗法试验未达主要终点：Biotech 事件驱动策略框架 Regeneron drops after skin cancer treatment misses late-stage trial goal The drugmaker's fianlimab-cemiplimab combination did not reach statistical significance in improving progression-free… FG 100 读报告 →